1619 National Celebration of Black Women

first_img1619 National Celebration of Black Women KUSI Newsroom Categories: Good Morning San Diego, Local San Diego News FacebookTwitter 00:00 00:00 spaceplay / pause qunload | stop ffullscreenshift + ←→slower / faster ↑↓volume mmute ←→seek  . seek to previous 12… 6 seek to 10%, 20% … 60% XColor SettingsAaAaAaAaTextBackgroundOpacity SettingsTextOpaqueSemi-TransparentBackgroundSemi-TransparentOpaqueTransparentFont SettingsSize||TypeSerif MonospaceSerifSans Serif MonospaceSans SerifCasualCursiveSmallCapsResetSave SettingsSAN DIEGO (KUSI) – 2019 marks the 400th year commemoration since the first slave ship arrived at Jamestown.In 1641, Massachusetts legalized slavery, specifying that a child inherited its status from the mother, rather than the father, reversing English common law.An event is scheduled for Saturday, March 2nd at 10 a.m. at Ruocco Park and it celebrates the strides that black women have made since 400 years ago when the first slave ship filled with African captives arrived along the shores of present-day Virginia. The City of San Diego proclaimed 1619 National Celebration of Black Women Day yesterday.For more information click here  March 1, 2019 Posted: March 1, 2019 KUSI Newsroom, last_img read more

Feds Yellen makes subtle shift in emphasis

first_imgFed’s Yellen makes subtle shift in emphasis1.5K viewsFed’s Yellen makes subtle shift in emphasis1.5K views00:00 / 00:00- 00:00:0000:00Fed’s Yellen makes subtle shift in emphasis1.5K viewsBusinessA subtle but powerful message adjustment from Fed Chair Janet Yellen speaking to the Senate Banking Committee about plans for the first interest rate hike since 2006: (SOUNDBITE) JANET YELLEN, CHAIRVentuno Web Player 4.50A subtle but powerful message adjustment from Fed Chair Janet Yellen speaking to the Senate Banking Committee about plans for the first interest rate hike since 2006: (SOUNDBITE) JANET YELLEN, CHAIRlast_img read more

MS Dhoni can never be a victim of Mankad Krunal Pandya are

first_imgMS Dhoni never left the crease in a potential ‘Mankad’ dismissal scenario.iplt20.comRavichandran Ashwin may well have started a trend in the Indian Premier League with his ‘Mankad’ dismissal of Jos Buttler when Kings XI Punjab met Rajasthan Royals on March 25 as Krunal Pandya tried to similarly send MS Dhoni back to the pavilion when Mumbai Indians met Chennai Super Kings at the Wankhede Stadium on April 3.The incident happened in the 14th over of CSK’s run chase and Krunal was bowling to Kedar Jadhav with the CSK captain at the non-striker’s end. Pandya was into his delivery stride when Dhoni was taking a start and moving along with the bowler towards the striker’s end. Instead of delivering the fifth ball of the over, the left-arm orthodox bowler simply completed his run up and rolled his arm over. He subsequently stared at the batsman but did not look at Dhoni.”Surely we won’t see this [Mankading] in IPL,” exclaimed Mathew Hayden on commentary as he noticed Mumbai Indians wicketkeeper Quinton de Kock sporting a wry smile. It must be noted that at no point did Dhoni’s bat leave the crease and even if Krunal had intended to knock the bails off, Dhoni would not be dismissed. “Yeah, right instincts for Dhoni – bat was inside, ball wasn’t seen. You know he does most things right. Just out of instincts with Dhoni, very rarely will you seem him do something that is incorrect,” commented Sanjay Manjrekar on air.There was no reference to this incident later on either but Dhoni spoke about where his team went wrong as CSK suffered their first defeat of the 2019 campaign of the IPL. “I think quite a few things went wrong for us. We started well, were right on the mark for the first 10-12 overs. Then, a few catches were dropped, a few misfields, the death overs bowling wasn’t great. We don’t have bowlers who hit the deck, it was slightly tough on them,” he remarked.CSK had started very well and was on top in the match till the 14th over of Mumbai’s batting as the home side had scored only 82 runs. But Krunal’s younger brother Hardik Pandya and Kieron Pollard spoiled CSK’s party at the death as they plundered 88 runs in the last six overs including a mammoth 29-run last over. MS Dhoni has a few injury concerns to take care of.Shaun Roy/IPL/SportzpicsThe last over was bowled by Dwayne Bravo who has since suffered a hamstring injury to rub salt into his and his team’s wounds. “We will have to see the wicket for the next game, we have to see the combination. Bravo has an hamstring injury, we don’t have a few players, we already have some injuries, David Willey isn’t there, he has his own problems, Lungi Ngidi isn’t with us as well, we will have to look at the pitch and then decide on the right combination,” Dhoni said after the match.CSK will head home to the MA Chidambaram Stadium next to face Ashwin’s KXIP on April 6.last_img read more

Akshaya Tritiya 2019 Significance date timings All you need to know

first_imgFor representational purposesReuters/Leonhard FoegeAkshaya Tritiya, also known as Akha Teej, falls on the third lunar day of the waxing moon, according to the Indian Vaishakha. In 2019, Akshaya Tritiya will be celebrated on Tuesday, May 7.On this day, many believe that Parusharam, an avatar of Lord Vishnu, was born on Akshaya Tritiya. It is also believed that the sage Ved Vyas began writing the Mahabharat on this day.On Akshaya Tritiya, Hindu households worship the Goddess Lakshmi. They buy cars, houses, and invest in new ventures. Many also buy gold on Akshaya Tritiya believing that the purchase of the jewellery would keep the Goddess happy. One of the reasons to buy gold is to make sure that there are jewellery two months before the Sharavana month which is a favourable time for engagements and marriages. For those not buying gold, who may bring a photo of Goddess Lakshmi’s feet and do a puja for them. Brahmins are advised to donate pots, food, sugar, ghee, for the happiness of their ancestors. Here are some Akshaya Tritiya wishes you can share with your loved ones on an auspicious daySanskrit Word Akshaya means one that never diminishes. May this day of Akshaya Tritiya bring you good luck and success which never diminishes. Happy Akshaya Tritiya.Buying gold is a popular activity on Akshaya Tritiya as it is the ultimate symbol of wealth and prosperity Gold and gold jewellery bought and worn on this day signify never diminishing good fortune. Happy Akshaya Tritiya.Akshaya Tritiya is a very sacred and auspicious day. There is a belief that valuables bought on this special day will bring prosperity, luck and success. So purchase gold of your wish. Happy Akshaya Tritiya.May Lord bless you on this auspicious day of Akshaya Trithiya, and May it be a new beginning of greater prosperity, success and happiness. Greetings on Akshaya Trithiya.last_img read more

After Sky and Punch Taverns what major companies could be the next

first_imgIBTimes VideoRelated VideosMore videos Play VideoPlayMute0:00/0:00Loaded: 0%0:00Progress: 0%Stream TypeLIVE0:00?Playback Rate1xChaptersChaptersDescriptionsdescriptions off, selectedSubtitlessubtitles settings, opens subtitles settings dialogsubtitles off, selectedAudio TrackFullscreenThis is a modal window.The media could not be loaded, either because the server or network failed or because the format is not supported.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window. COPY LINKAD Loading … Close Sky stock prices have jumped 30% since Rupert Murdochs News Corp bid £11.2billion for the remainder of the company.center_img After Sky and Punch Taverns, what major companies could be the next takeover targets?last_img read more

Tamil Nadu Islamist terror group Ansarulla busted NIA arrests two

first_imgThe NIA, on Saturday, raided multiple locations in Tamil Nadu on a tip-off that some people were conspiring to wage a war against India.IANSAfter busting terror gang Ansarulla in Tamil Nadu, the National Investigation Agency (NIA) has arrested two people for their alleged links to the group that seeks to establish Islamic rule in India.Hassan Ali, 28, and Harish Mohamed 32, were arrested after the NIA raided their residences in Tamil Nadu’s Nagapattinam on Saturday, following inputs about their links with the terrorist group.The NIA had on July 9 filed a case against Ansarulla under various sections of the Indian Penal Code and the Unlawful Activities (Prevention) Act after it learnt that members of the group had collected funds and made preparations to carry out terrorist attacks in India.On Saturday, it raided multiple locations in Tamil Nadu on a tip-off that some people were conspiring to wage a war against India.Other than the residences of Ali and Mohamed, the NIA also searched the homes and offices of others, including one Syed Bukhari in Chennai.Nine mobiles, 15 SIM cards, seven memory cards, three laptops, five hard discs, six pen drives, two tablets, three CDs/ DVDs as well as a large number of documents, including magazines, banners, notices, posters and books were seized in these searches.”Based on incriminating facts revealed during the searches in Nagapattinam as well as Chennai in Tamil Nadu, and subsequent investigation accused Hassan Ali and Harish Mohamed were arrested on Saturday,” said an NIA official.”They will be produced before a special NIA court in Chennai this afternoon. Bukhari is still being examined,” he added.last_img read more

3 awarded death penalty one 20yr jail for war crimes

first_imgwar crimesThe International Crimes Tribunal (ICT) on Tuesday sentenced three war criminals to death and one another to 20-year jail for crimes against humanity committed during the 1971 liberation war in Sudharampur upazila of Noakhali district.The three condemned convicts are – Amir Ahmed alias Amir Ali, Abul Kalam alias AKM Mansur, Md Joynul Abedin. Abdul Kuddus was sentenced to 20-year jail.Of them, Abul Kalam alias AKM Mansur has been on the run.A three-member ICT bench led by justice Md Shahinur Islam pronounced the verdict, said prosecutor Jahid Imam.Earlier on 6 February, the tribunal concluded the hearing of arguments from both sides on the trial of four men for their alleged involvement in crimes against humanity conducted during the liberation war in 1971 in Noakhali’s Sudharampur upazila and kept the verdict pending for any day.The prosecution pressed charges against five people, including the four in the war crimes case. As another accused of the case, M Yusuf, died after the pressing of the charges, the deceased was not indicted.On 20 June 2016, the tribunal framed three specific charges against four people for their alleged involvement in crimes.The investigators started the probe against the five suspected war criminals on 16 November 2014 and submitted a report before the prosecution on 31 August, 2015.Three charges include killing of over 100 people, including 41 of Sonapur and Sreepur villages, in Sudarampur upazila on 15 June 1971.last_img read more

Two BNP leaders picked up by plainclothesmen

first_imgJashore district BNP general secretary Syed Sabbarul Haque Sabu and Jashore city BNP president Maruful IslamTwo local leaders of Bangladesh Nationalist Party in Jashore have been picked up by a team of plainclothes police on Thursday evening, alleged Jashore BNP while police has denied the allegation.They are Jashore district BNP general secretary Syed Sabbarul Haque Sabu and Jashore city BNP president Maruful Islam.One of the witnesses, district Juba Dal president Tamal Ahmed told the media that the incident occurred while the two leaders were distributing food among destitute people in front of the Zila School on Bangabandhu Sheikh Mujibur Rahman Road.A team of plainclothes police, in cars and on motorcycles, picked the leaders at around 5:45pm, Tamal added.The general secretary of Jashore city BNP Munir Ahmed Siddiqui said, ‘Saberul Haque and Maruful Islam were on bail. Yet the DB police have arrested them.”Munir Ahmed said, “It is very sad that police has arrested the leaders from such a non-violent program before Eid.”Asked officer-in-charge (OC) Md Moniruzzaman said, “no team of Jashore DB police has picked any BNP leaders.”Jashore Kotwali police station OC Abdul Bashar said he did not know anything about whether or not any BNP leaders were arrested.last_img read more

Funny side up

first_imgIt is widely believed that comedy is a genre that is the most difficult to master and perform. It is even more challenging in the sphere of performing arts. To elicit laughter from a specific audience takes a great deal of talent, charisma and impeccable comic timing. The cast of One on One Part 2, who performed in the Siri Fort auditorium on Sunday managed to have the audience in splits.In order to stay relevant in an age where the cinema viewing experience is growing by leaps and bounds, theatre has to re-invent itself and that is precisely what One on One Part 2 attempted to do. Also Read – ‘Playing Jojo was emotionally exhausting’A far cry from the type of theatre we are accustomed to, this act presented a series of monologues to its audiences which served as a commentary to various social issues ranging from the trials of a married woman who struggles with motherhood to the futility of war along with the aftermath of the tragic Nepal earthquake, the tribulations of a ticket checker stuck at a job at a place where the citizens think they are above the law and the aspirations of a girl who initially wanted to get married but after the act realises she has made a grave mistake.  The sketches were predominantly comical, but had an underlying social message. Also Read – Leslie doing new comedy special with NetflixWith the right mix of veteran talents and fresh blood, the acting aspect of the play was top notch. Headlined by notable names such as Rajit Kapoor, Anu Menon( of Lola Kutty fame), Neil Bhoopalam( NH10, Shaitan, No One Killed Jessica) and lesser known faces such as Shikha Talsania, Gopal Dutt and Sumeet  Vyas, the pace of the play never slackened. Shikha as the new bride who develops cold feet after marriage was a revelation while Gopal Dutt as the ticket checker displayed immense comic abilities. However, the real star of the show was Sumeet Vyas who essayed roles of an army man as well as a first-time producer with aplomb. His depiction of a producer who is constantly heckled by the director, the assistant director, the superstar as well as the spot boy was a treat to watch as it was tinged in realism. Neil Bhoopalam, Anu Menon and Rajit Kapoor also left an indelible mark on the audience with their measured performances.Directed by a host of directors like Rahul DaCunha, Rajit Kapoor, Nadir Khan, Sumeet Vyas, Ashish Jagtiani and Hussain Dalal, there was never any doubt about the credibility of the act and it sure didn’t disappoint. With such innovative ideas getting incorporated in contemporary theatre, it’s no wonder it still commands a certain amount of following, even in this age of three-dimensional films.last_img read more

Court summons Amit Shah in defamation case filed by Abhishek Banerjee

first_imgKolkata: The Chief Metropolitan Magistrate (CMM) has summoned BJP national president Amit Shah to appear before the Court on September 28 in connection with an alleged defamation case filed by Abhishek Banerjee, Trinamool Congress MP and president of the All India Trinamool Youth Congress.On August 11, Amit Shah had made certain defamatory statements against Abhishek at the BJP’s Yuva Swabhiman Samavesh rally on Mayo Road. Shah had said that the funds released by the Centre worth Rs 3.59 lakh crore to Bengal ended up with Abhishek, who is Chief Minister Mamata Banerjee’s nephew, and syndicates. Also Read – Rain batters Kolkata, cripples normal life”The residents of the villages in Bengal, has the money reached your village? Prime Minister Modi had sent it. Where did Rs 3,59,000 crore go? This has been gifted to the nephew and the syndicate,” Shah had said in the rally. “Narada, Saradha, Rose Valley, syndicate’s corruption, nephew’s corruption… a series of corruption have been carried out under Mamataji,” Shah had said. These statements were widely published and circulated all over the country in various newspapers and on social media. Also Read – Speeding Jaguar crashes into Mercedes car in Kolkata, 2 pedestrians killedOn August 13, Banerjee’s advocate had served a notice to Amit Shah, calling upon the accused to retract such virulent and mala fide defamatory statements and to issue an unconditional apology to the complainant. No response was received by Abhishek Banerjee or his advocate. Later, a complaint case was filed on August 28 before the CMM by the complainant under Section 500 of the Indian Penal Code (Punishment for defamation). Cognizance was taken by the CMM on August 28. On Wednesday, the application was fixed for examination of the complainant and the witnesses, when Abhishek Banerjee as well as the witnesses, Swarup Biswas and Soumya Bakshi appeared and made their statements, on oath, before the CMM.last_img read more

The best of Aussiestyle offroad camping from the 2019 Australian 4×4 Outdoor

first_img Darche’s huge range of car-mounted camping gear can turn any 4WD into a multi-story complexLoz Blain/New Atlas What is the mechanism of action for mepolizumab? Read about it at Allmedx.com. One of the more expensive trailers at the expo, the AU$76,720 (US$52,000) Zenith is a nuggety, aerodynamic and tough pod camper with extendable awnings, pop-out kitchenware and a fold-out entrance tent to give you a bit of hang-out space when the weather turns wet or hot.Austrack’s tiny Simpson rooftop trailer Google Analytics settings A pricey bit of kit at AU$75,990 (US$51,500), the Nexus 360 builds on Ultimate’s previous offerings to offer king bed comfort, sleeping quarters for as many as seven people, external cooking and BBQ, hot water, heating, carbon benchtops and a 360-degree awning all round, folding down into a super-compact, aerodynamic and funky looking package.Alu-Cab’s pop-top camper fitouts The monstrous CRZRVAN The interior of the Air Opus OP2 is so huge you can barely touch the ceilingLoz Blain/New Atlas So fresh the company doesn’t even have a website yet, CRZRVAN (pronounced cruiservan) is making gigantic, super-heavy-duty hard-top caravans that look like they belong to a private militia on the outside, but are decked out in super-stylish luxury in the interior, as shown below. AluCab does its compact, quick setup thing to a Toyota LandcruiserLoz Blain/New Atlas Global Explorer 4×4, by Australian Outback Adventure Patriot’s retro X1-N Desert Ops trailerLoz Blain/New Atlas Starting at AU$181,000, the Global Explorer 4×4 is a Mitsubishi Fuso Canter built into something you could almost enter in the Dakar, but with a luxury camping interiorLoz Blain/New Atlas Austrack’s tiny AU$17,990 Simpson is a Swiss army knife of a camper trailer, with fridges, cooking gear, 100 liters of water, a rooftop tent, awnings, hot shower, portaloo and a stereoLoz Blain/New Atlas What role do eosinophils play in asthma? Discover what researchers have to say on Allmedx.com The CRZRVAN: absolutely colossalLoz Blain/New Atlas Track’s pretty TVAN Zenith Mk5 isn’t cheap, at AU$76.720, but it’s bulletproof for off-roading, and offers you the ability to pop the back and jump in for a quick snooze, or dropping the floor and deploying a tent for longer staysLoz Blain/New Atlas Starting at AU$16,990, this pop-top Tommy Campers slide-on sits in your back yard on legs, and then attaches to your ute tray with just four big bolts to turn your work vehicle into a weekend off-road playthingLoz Blain/New Atlas These retro colors are back in style, and if you can’t pick up a good thrift shop polo-shirt from the 70s, the next best thing might just be this monster twin cab Land Cruiser conversion that Patriot’s built specifically to haul its equally funky X1-N Desert Ops trailer below. Check out the full story here. The AU$75,990 Ultimate Nexus 360 is a compact, super-aerodynamic, heavy duty off-road trailer that unfolds to sleep between two and sevenLoz Blain/New Atlas The Air Opus OP2 inflatable camping trailer, at AU$28,990, pops up into an absolutely cavernous living space in a minute or two, and is still a dazzling standout Loz Blain/New Atlas I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more 23Zero’s range of roll-up swags – small, roll-up mini-tents wth mattressesLoz Blain/New Atlas Fold-out living accommodations up top, everything else underneath. The Simpson X is a super-tough, very compact two-person camper that comes fully set up with awning, water tank, fridge/freezer, hot shower, portaloo, solar power and gas cooktops for AU$17,990 (US$12,200.) Check the gallery for other similar options from companies like Stoney Creek Campers.Isuzu’s D-Max and MU-X concepts Can mepolizumab improve quality of life in patients with asthma? Learn more at Allmedx.com. Another way to get going quickly and relatively cheaply is to festoon your 4WD with pull-out and pop-up accessories. Darche hit the expo with a dazzling range of reasonably priced camping gear ready to turn any “fourby” into a multi-story outback hotel.Patriot’s Land Cruiser Desert Ops Supertourer The massive Isuzu MU-X Concept made its debut at Aus4x4, with its 38-inch tires and seven inches of liftLoz Blain/New Atlas The massive Isuzu D-MAX concept has a totally bespoke tray as well as a monster 7-inch lift on the suspensionLoz Blain/New Atlas AllMedX Business at the front, party at the back. The great Aussie ute gets a super-neat camping accessory that sits in your backyard on legs when it’s not in use, leaving your ute tray free for weekday activities. Then, when it’s time to let your hair down and hit the great outdoors, you can back up and bolt the Tommy Camper on in minutes, to make a comfy and well-appointed camper out of any pickup.Ultimate Nexus 360 Track Trailer’s 2019 Zenith Mk.5 For less than AU$10,000 (US$6,800), Alu-Cab will equip your 2007-onwards Landcruiser with a rooftop tent and 270-degree awning. Simple and effective.There’s a ton more in the gallery, jump in and enjoy the best from down under.Source: Australian National 4×4 Offroad Expo When you ain’t got much money or much interest in fiddling about with tents, the great Aussie swag is a quick, cheap way to sleep under the stars. Most come with a mattress, and they roll up into canvas bags you can chuck in most any car’s boot. That’s throw in the trunk for our American cousins. These are by 23Zero, but there are dozens of companies making them.Darche’s 4WD camping add-ons How does mepolizumab relieve symptoms of asthma? Visit Allmedx.com for information. AllMedX The retro theme continues with Patriot’s Land Cruiser-based Desert Ops SupertourerLoz Blain/New Atlas A pair of monster off-roaders with 38-inch wheels, 7-inch lifts on the suspension and custom bodywork in the name of super-tough off-road cred. Check the MU-X below. AllMedX Powered by We’ve seen the Air Opus gear and its self-inflating pop-up canopy before, but it just doesn’t get old – and the absolutely cavernous living space it creates has ceilings so high you can barely touch them. At AU$28,990 (US$19,660), it’s a terrific option at the lower end of the mid range. Take a look at what this thing looks like inside: AllMedX We recommend AllMedX AllMedX What are the treatment options for chronic asthma? Learn more about the condition at Allmedx.com. What treatments are available for severe asthma? Find out the latest treatments on Allmedx.com. Inside the massive CRZRVAN P4Loz Blain/New Atlas Take one Mitsubishi Fuso Canter light truck, spec it up with chunky 37-inch super single wheels and stick a luxury camper on the back, and you’ve got the Global Explorer, a gigantic two-person transcontinental tourer costing AU$181,400 (US$123,000). Interior photos in the gallery.The Air Opus OP2 “inflatable” trailer Privacy policy Tommy Campers’ slide-on ute camper Yes No Australia is nearly the size of the United States, but has less than a tenth of its population, mainly dotted around the perimeter. It’s a rough, rugged and beautiful country, and it offers some of the toughest and most rewarding camping on the planet. The off-road industry is perenially strong in Australia, and has a style all of its own. Heavy duty, go-anywhere camper trailers and rugged hybrid caravans are the order of the day, with a few other ideas based around the well-known Aussie love affair with the “ute,” or pickup truck. Here are our favorite picks from the Australian 4×4 Outdoors Expo in Melbourne.The Humble Swaglast_img read more

WestJet rolls out the blue carpet for travel agents

first_img Friday, October 28, 2016 Tags: WestJet, WestJet Vacations << Previous PostNext Post >> Posted by Tweet TORONTO — WestJet and WestJet Vacations welcomed travel agents and travel industry partners to the fourth annual WestJet 2016 Travel Partner Awards, held last night in Toronto at the Four Seasons Hotel.Over 200 guests attended the cocktail party and gala, toasting their relationship with a WestJet Platinum cocktail – a mix of prosecco, grapefruit juice and blue curacao – which resembled the company’s trademark shade of blue, before a lavish dinner in the sparkling Aria Ballroom.WestJet’s Vice-President of Sales, Lyell Farquharson officially welcomed attendees and explained that the awards were “a way to recognize our partners in front of their peers. Many of our partners are growing along with us, and it’s great to see us growing together.”Hosted by WestJetters Tim Paul (Manager, Sales Strategy and Planning) and Matt Djorsev (Business Development), 13 awards were handed out based on sales criteria of the past year by travel partners.Interspersed with ticket giveaways to WestJet destinations and prizes from sponsors AMResorts, Barbados Tourism Marketing Inc., and Bahia Principe Hotels and Resorts, hosts Tim and Matt entertained the crowd with jokes and a few self-deprecating comments, such as recent news that a WestJet airplane had to be diverted to Greenland last week.More news:  Air Canada’s global sales update includes Managing Director, Canada & USA SalesFarquharson and Jane Clementino, WestJet’s Director of Agency Sales, handed out the following awards:Top Growth Canadian Tour Operator Sales – Voyzant Inc.Top Online Agency – Expedia.caTop Group Incentive Convention Sales – Uniglobe TravelTop Sales Barbados – Transat Travel Travel Distribution CentreTop US Agency – Travel LeadersWestJet Encore Top Sales – American Express Global Business TravelTop Sales AM Resorts – Ensemble Travel GroupWestJet Vacations Top Guest Count Growth – Redtag.caWestJet Vacations Top Revenue Growth – Flight Centre Travel GroupTop Sales Bahia Principe Hotels & Resorts – Flight Centre Travel GroupTop Growth Travel Management Company – HRGTop Guest Count Growth – Travel Nation CanadaTop Revenue Growth – Merit TravelWestJet Airlines Ltd. Is celebrating its 20th anniversary in 2016 and was recognized by the Peter B. Gustavason School of Business at the University of Victoria as Canada’s most trusted airline this month. Waheeda Harris WestJet rolls out the blue carpet for travel agents About Latest Posts Waheeda HarrisA traveller from a young age, Travelweek contributor Waheeda Harris is pop culture obsessed, loves spicy food and is happy to wander around our planet with her camera in hand. Latest posts by Waheeda Harris (see all) Celebrity Equinox, Celebrity Edge stars of JetSet3 fam – April 23, 2019 Unleash the power of cross-company digital transformation to revolutionize your CX – February 8, 2019 On location: Cabo San Lucas welcomes the stylish Riu Palace Baja California – December 20, 2018last_img read more

April 9 2004 Congratulations to March 7 work

first_imgApril 9, 2004 Congratulations to March 7. workshop participants for completing their 5 week program today. >>top from left: Luigi Ciaccia, Jack Appelt, Sean Smith, Mark Baris, Dino Orsato, Guido Parigi and workshop coordinator Kelli Huth. >>middle from left: Chieko Shimizu, Takeshi Notsuki, Tomoya Shiota and Haruhisa Nakada. >>bottom from left: Jacob Schwartz, Ryoko Yamanaka, Maki Minakuchi and Takako Ueyama. [Photo & Text: sa]last_img

Belgian telecom operator Proximus added 11000 TV

first_imgBelgian telecom operator Proximus added 11,000 TV customers to its base in the third quarter, taking its total to 1.595 million, up 3.4% year-on-year.Dominique LeroyThe telco had 8,000 new fixed internet customers over the same period, taking its total to 2.01 million, up 2.3% year-on-year.Overall, Proximus posted revenues of €1.095 billion for the quarter, down 0.9% thanks to lower mobile device revenue. EBITDA was up 1.1% to €431 million, thanks higher direct margins attributed to a growing customer base, focus on value management and on the impact of acquisitions in the enterprise segment.Proximus CEO Dominique Leroy said that the company’s segmentation strategy was paying off. She said that the Proximus brand was now delivering “a more valuable customer base” thanks to the success of Tuttimus and Bizz All-in offers, which counted 477,000 subscribers at the end of September.last_img read more

Third Celsions LTSL technology promotes an accel

first_img Third, Celsion’s LTSL technology promotes an accelerated release of the drug when and where it will be most effective. That allows for direct targeting of organ-specific tumors. Celsion’s LTSL technology has shown that it’s capable of delivering drugs to the tumor site at concentrations up to 30 times greater than those achievable with chemotherapeutics alone, and three to five times greater than those of more traditional liposome-encapsulated drug-delivery systems. The company’s first drug under development is ThermoDox, which uses its breakthrough LTSL technology to encapsulate doxorubicin, a widely used chemotherapeutic agent that is already approved to treat a wide range of cancers. Currently, ThermoDox is undergoing a pivotal Phase III global clinical trial – denoted the “HEAT study” – for the treatment of primary liver cancer (hepatocellular carcinoma, or HCC), in combination with radiofrequency ablation (RFA). RFA uses high-frequency radio waves to generate a high temperature that is applied with a probe placed directly in the tumor, which by itself kills tumor cells in the immediate vicinity of the probe. Cells on the outer margins of larger tumors may survive, however, because temperatures in the surrounding area are not high enough to destroy them. But the temperatures are high enough to activate Celsion’s LTSL technology. Thus, the heat from the radio-frequency device thermally activates the liposomes in ThermoDox in and around the periphery of the tumor, releasing the encapsulated doxorubicin to kill remaining viable cancer cells throughout the region, all the way to the tumor margin. ThermoDox is also undergoing a Phase I/II clinical trial for the treatment of recurrent chest wall (RCW) breast cancer (known as the “DIGNITY study”), and a Phase II clinical trial for the treatment of colorectal liver metastases (the “ABLATE study”). But most of the drug’s (and hence the company’s) value is tied up in the HEAT study. The HEAT trial is a pivotal 700-patient global Phase III study being conducted at 79 clinical sites under a special protocol assessment (SPA) agreement with the FDA. The FDA has designated the HEAT study as a fast-track development program, which provides for expedited regulatory review; and it has granted orphan-drug status to ThermoDox for the treatment of HCC, providing seven years of market exclusivity following FDA approval. Furthermore, other major regulatory agencies, including the European Medicines Agency (EMA) and China’s equivalent, have all agreed to use the results of the HEAT study as an acceptable basis to approve ThermoDox. The primary endpoint for the HEAT study is progression-free survival – living longer with no cancer growth. There’s a secondary confirmatory endpoint of overall survival, too. Both the oncological and investing community are eagerly awaiting the results, which are due any day now. So then, why are we on the sidelines now, right when the big news is due to hit? That all goes back to why Celsion was such a good investment to begin with, and what it can tell us about finding other big wins in the technology stock market. A Winner in the Making When we’re looking for a strong pick in the biotechnology, pharmaceuticals, and medical devices fields – once we have established the quality of the technology itself and ensured it will likely work as expected – there is a simple set of tests we apply to ensure that we’ve found a stock that can deliver significant, near-term upside. The most critical of these are: The technology must provide a distinct competitive advantage over the current standard of care and be superior to any competitors’ effort that will come to market before or shortly after our subject’s does. In other words, it must improve outcomes, by improving patients’ length or quality of life (i.e., a cure for a disease, or a maintenance medication with fewer side effects), or lower costs while maintaining quality of care (i.e., a generic drug). A therapy that does both is all the better. There must a clear path to market in the short term, or another catalyst to propel the stock upward. An investment in a great technology does not always make for a great investment. You have to consider the quality of the management team and structure of the company, including its ability to pay the bills and get to market without defaulting or diluting you out of your positions. And of course, time. The biggest and most frequent mistake investors make in technology is assuming that it is smooth and short sailing from concept to market. Reality is much harsher than that, and in biotechnology and pharmaceuticals in particular – with a tough regulatory gamut to run – the timeline to take a new technology to market can be anywhere from a decade to thirty, forty, or even fifty years. Liposomes are a perfect example of that. Twenty years ago, I probably could have told you a story about a technology that was very similar to what was laid out above. It would be compelling and enticing to investors of all stripes – a breakthrough technology with the promise to revolutionize cancer care by making chemo less toxic and more effective at the same time. Yet had you invested in that promise alone, chances are you’d be completely wiped out by now, or maybe – just maybe – still waiting for a return. That is why we invest in proof, not promises. So, how does Celsion stack up against our four main proof points? Time to market: When we first recommended Celsion, it was in Phase III pivotal trials. This is the last major stage of human testing usually required before a company can submit an FDA New Drug Application and apply to market the product. The process of bringing a drug to market, even once a specific compound has been identified and proven to work in vitro (in the lab), is perilous. Many things can go wrong along the way. If you look at investing in a company whose drugs are just entering Phase I clinical trials, for instance, it is still unclear if the therapy is effective in vivo (in the human body). This is a critical stumbling block for many companies, whose promising compounds immediately prove less effective or more dangerous than testing suggested. Even if Phase I goes well, it can take up to a decade and sometimes longer to get from there to market with a drug. And then, even Phase II trials often leave treatments five or more years from market – though there are exceptions in cases where a therapy is proven very effective or a disease has so few treatment options available. But shortcuts are rare, and investors have to consider the time and expense (which leads to fundraising and ultimately dilutes your return) of getting from A to Z. In this regard, Celsion made a uniquely great investment. When we first recommended the company, it was in the midst of a pivotal Phase III trial and looked to be about a year or so away from its first commercialization. (Though, speaking to the length of these trials, this one had been started back in 2008.) With many of the most high-profile companies in the industry – those working on vogue treatment areas and conditions, like hepatitis C treatments of late – when they get this close to market, the large banks bid up stocks to high levels, content to squeeze just a few percentage points out at the end. They have to be conservative, since they’re investing large amounts of other people’s money. However, biotechnology is such a fragmented space with far more companies than Wall Street can possibly cover in depth, that coming across a gem like Celsion late in the game with a potentially big win is not as uncommon as you’d think. The “efficient market” hypothesis fails to account for the fact that no one can know everything, including every stock. And Celsion had gone all but unnoticed for some time. Payer acceptability: Celsion has the benefit of developing a 2.0-style product, an improvement over something that already exists. RFA is already in relatively widespread use and has proven effective enough that most every insurance and benefits provider will cover it. Even the early generations of LTSL, while not quite as safe or effective as desired, were enough of a benefit to gather pretty solid support from payers. Celsion, through its clinical trial process, has proven its unique blend is safer, better tolerated by patients, and much more effective than its predecessors. Thus, payer support at a reasonable price is a pretty sure bet. Market size: When we originally recommended Celsion, we stated that the company was sitting on a multibillion-dollar opportunity. And we stand by that statement. However, just because something is eventually worth that amount does not mean it’s bankable today as a short-term investment. So we try to keep our analysis narrowly focused on what can be directly counted on and measured. In Celsion’s case, that’s the Phase III treatment, Thermodox, and the one area in which it is being studied: primary liver cancer (HCC). Even just in this narrow band, however, we see the market opportunity for Celsion as in excess of $1 billion. HCC is one of the most deadly forms of cancer. It currently ranks as the fifth most-common solid tumor cancer, and it’s quickly moving up. With the fastest rate of growth among all cancer types, HCC projects to be the most prevalent form of cancer by 2020. The incidence of primary liver cancer is nearly 30,000 cases per year in the US, and approximately 40,000 cases per year in Europe. But the situation worldwide is far worse, with HCC growing at approximately 750,000 cases per year, due to the high prevalence of hepatitis B and C in developing countries. If caught early, the standard first-line treatment for primary liver cancer is surgical resection of the tumor. Early-stage liver cancer generally has few symptoms, however, so when the disease is finally detected, the tumor is usually too large for surgery. Thus, at least 80% of patients are ineligible for surgery or transplantation by the time they are diagnosed. And there are few nonsurgical therapeutic treatment options available, as radiation and chemotherapy are largely ineffective. RFA has emerged as the standard of care for non-resectable liver tumors, but it has limitations. The treatment becomes less effective for larger tumors, as local recurrence rates after RFA directly correlate to the size of the tumor. (As noted earlier, RFA often fails at the margins.) ThermoDox promises the ability to reduce the recurrence rate in HCC patients when used in combination with RFA. If it proves itself in Phase III, there’s no doubt the drug will be broadly adopted throughout the world once it is approved. A quick look at the numbers: According to the most recent data from the National Cancer Institute, the incidence rates of HCC per 100,000 people in the three major markets are 4 in the US, 5 in Europe, and approximately 27 in China. Based on these incidence rates, the total addressable market in these three regions (which we will conservatively assume to be the total addressable worldwide population for the time being) is approximately 400,000 (12,000 in the US, 40,000 in Europe, and 351,000 in China). Assuming that 50% of HCC patients are eligible for nonsurgical invasive therapy such as RFA, approximately 200,000 patients worldwide would be eligible for ThermoDox. Further assuming an annual cost of treatment for ThermoDox of $20,000 in the US, $15,000 in Europe, and $5,000 in China, in line with similar treatments of the same variety, we estimate that the market potential of ThermoDox could be up to $1.3 billion. Not to mention the countless thousands of lives saved. (And that’s before the rest of the developing world comes online.) Of course, this is an estimate of ThermoDox’s potential assuming 100% market penetration – something that simply never happens. While we expect ThermoDox in combination with RFA to become the standard of care for primary liver cancer, a more reasonable expectation for maximum market penetration after a six-year ramp-up to peak sales (from an expected approval in 2013) is probably 40%. Improving outcomes or lowering costs: This is exactly what the Phase III trial was intended to prove: efficacy beyond a shadow of a doubt. Given preliminary data and earlier trial results, it was already a pretty sure thing, so in our model, we assumed about a 70% chance of success (to be on the conservative side, as always – it’s better to be right by a mile than to miss by an inch). Once we incorporate that probability of success into our model, we come to a probability-weighted peak sales figure in 2019 of approximately $365,000,000 annually. The average-price-to-sales ratio among the big players in biotech these days is about 5. If we apply a sales multiple of 3 (i.e., just 60% of the average) to Celsion’s probability-weighted peak sales for ThermoDox in 2019, we come up with a value for the company of nearly $1.1 billion, which would equate to about $33 per share if it did not issue any new stock between now and then – that’s more than 17 times where the stock was trading when we recommended a buy. And remember, these numbers are only for ThermoDox under the HCC indication. Our Move to the Sidelines With final data from the current Phase III pivotal trial due expected to come in within the next few weeks, Celsion’s stock has ballooned in value from the $2 range to $7.50 or so in the past few weeks. Now, that’s a far cry from the $33 price we mentioned above, but remember, that’s a target for 2019. And it doesn’t allow for a whole range of things that could go wrong. Chief among those concerns is that the Phase III data come in more poorly than expected. Even just a small variance in efficacy or a simple question about safety can knock a few hundred million dollars off those sales figures. Or it can push trials back a year or two, delaying returns and sending short-term-minded investors, like those who have recently bid up CLSN shares, retreating to the hills for the time being. Further downfield there is sure to be competition as well, and of course we may get those miraculous chemo-free treatments mentioned up front. In short, we don’t have a crystal ball and can’t tell you what the world will look like in 2019. If you believe yours is clear, ask yourself if you thought touchscreen phones and tablets would outsell traditional computers by 3 to 1 globally in 2012. If not, you might want to give the crystal a polish. To be clear, the value of Celsion in the near term hinges on a binary event – the results of the ongoing HEAT trial. We are of the opinion that CLSN represents one of the best opportunities we’ve come across since we started this letter, and that the probability of a successful trial is high. Nevertheless, there is substantial down side if the trial is unsuccessful. And it could take years to recover, if ever, on news of a delay from any concerns raised. We’d already advised subscribers to take a free ride early on in our coverage of the stock, taking all of the original investment risk away. However, even with that protection, the short-term potential is still more heavily weighted to the down side. Thus, we booked our profits and stepped to the sidelines on this one. Celsion continues to be a model, even at today’s prices, for a great biotech investment with significant upside potential. But we’re content to wait for the market to hand us another, similar opportunity. The pages of Casey Extraordinary Technology are filled with investments just like Celsion – up-and-coming technology companies the market has yet to discover. Subscribe today and save 25% off the regular price, as always backed by our unconditional money-back guarantee. Bits & Bytes More 3D-Printer Magic (Gizmag) Last week, we noted some of the cool things people are doing with 3D printers. But it’s hard to keep up. The tech is blasting ahead so fast that this week we couldn’t resist adding another. Researchers at the University of Warwick, already known for its cutting-edge tech research, have created a cheap, plastic composite that can be used even with low-end 3D printers to produce custom-made electronic devices. The potential here is staggering. Tablets – Hotter than We Thought (Computerworld) Global market-research company IDC has revised its estimate for sales of tablets for 2012 upward by 4.5%, to 122.3 million units. Apple is expected to lose market share to surging Android-based devices. Whose Internet Is It? (GamePolitics) Well, the US Congress appears to think it’s the people’s. Other countries disagree, and have been trying to wrest control of the ‘Net from our hands for a while now. Many want the UN in charge. But this week, the House unanimously passed a Senate resolution calling on the US government to officially oppose any transfer of Net control to the UN. We’d guess this battle is far from over, though. Tattoo You? (Gizmag) Next time you see a runner with a smiley-face tattoo on his or her arm, you might be looking at a sophisticated metabolic sensor, designed to detect stress due to exertion. Of course, we aren’t always in a smiley frame of mind, are we? So if we could just cross one of these things with a mood ring… We are not ones for bragging about our accomplishments. Whether you believe in such mystical forces as karma or not, it’s generally a good rule that those who take too much credit for their successes are soon rewarded with a streak of the opposite, just to keep them humble. However, it is just as important to take stock in your achievements as it is your failures, if you are going to learn and grow as an investor (or in any pursuit). As such, this week I want to introduce you to the story of a company that we recommended to our investment advisory subscribers back in April 2012. It’s since gone on to gain significantly. The stock rose 297% from our initial recommendation to the day the “sell” call was made. What’s important about this small company is why it made our investment list to begin with, and what its characteristics can tell us about successful speculation in the arena of up-and-coming technology companies. Sincerely, Alex Daley Chief Technology Investment Strategist Casey Research Anatomy of Great Technology Investment By Alex Daley, Chief Technology Investment Strategist Traditional cancer treatment options are little more than a crude mix of “slash, burn, and poison” – that is surgery, radiation, and chemotherapy. There are radical new treatments in labs and trials all over the world that promise to throw out this trifecta; no other disease has received more of the research interest and funding that have defined modern biotechnology over the past three decades. I’m not going to tell you about any of those here. Sure, many of them will be wildly successful and make many investors fabulously wealthy over the next few decades. But most will fail. And those that don’t will take a long time to turn a profit for investors. Yet, there is one small company whose unique twist on cancer treatment is proving to be a major upgrade. We profiled this company in a recent edition of Casey Extraordinary Technology, and it turned in a gain of over 167% for subscribers in just six months’ time. It may yet make billions more still for investors. You see, in recent years chemotherapy has become the core treatment for most cancerous malignancies. And while these toxic cocktails of chemicals have proven effective at destroying cancerous cells, they also have one problem. A big one. Chemo, being essentially a poison, doesn’t just attack cancerous cells – it attacks a broad range of healthy cells too. As a result, the treatment can sometimes be as harmful as the cancer itself in the short run. The side effects are awful, and its use can quickly erode patients’ health. Some have even described chemo as a “cure that’s worse than the disease.” This sad state of affairs for the world’s second most-prevalent chronic disease is why the cancer-research arena has been exploding over the past few years with the goal of developing more targeted, less-toxic therapies – in other words, to do a better job killing cancer cells while leaving healthy cells alone. That’s exactly what Lawrenceville, New Jersey-based Celsion Corp. (CLSN) has the technology to do. And chances are the company is on to one of the biggest cancer-treatment breakthroughs in decades. How It Works Our story starts with liposomes. These nanosized artificial vesicles are made from the same material as our cell membranes – natural phospholipids, i.e., a version of the chemicals that make up everything from fat to earwax, and cholesterol. Not long after their discovery in the 1960s, scientists began experimenting with liposomes as a means of encapsulating drugs, especially cancer drugs. Why? Something called the “enhanced permeability and retention” (EPR) effect. This is a property of certain sizes of molecules – for example, liposomes, nanoparticles, and macromolecular drugs – which tend to accumulate in tumor tissue much more than they do in normal tissues. It’s a useful feature for a cancer drug. Thus, they offer a potential way to combat the two biggest drawbacks of traditional chemotherapeutics: systemic toxicity and low bioavailability at the tumor site. In other words, the drugs now employed are themselves are toxic to normal cells, and they tend to get largely used up before they even reach the tumor site. Early attempts to encapsulate drugs inside liposomes did an okay job of dealing with the toxicity issue, but bioavailability at the tumor site was still limited. Our immune system saw to that. Just like virtually anything else artificial we put into our bodies, traditional liposomes were seen as invaders. Thus, they were rapidly cleared by the mononuclear phagocyte system, the part of the immune system centered around the spleen (yes, we do use it) that destroys viruses, fungi, and other foreign invaders. However, a breakthrough arrived when scientists came up with a new way to sneak these artificial compounds into the body undetected by our defenses. The process gave us what are call “PEGylated” liposomes, with a covalent attachment of polyethylene glycol polymer chains. The effect of attaching these little plastic chains to the end of the liposome was to create a “stealth” liposome-encapsulated drug that was hardly noticed by the system. Problem solved, right? Well, not exactly. A lot of hard work went into getting drugs into liposomes to reduce toxicity, then a bunch more into stopping our immune system from kicking in. But there was still yet another problem. The drug-release rates of these stealth liposomes were generally so low that tumor cells barely got a dose. Scientist had made them so stealthy that they even skated right by cancer cells, usually failing to kill off the tumors. After decades of experimenting with liposome-encapsulated cancer drugs, scientists still had not been able to safely deliver therapeutic concentrations of the chemotherapy drugs to all tumor cells. They had to devise a way to induce drug release when and where it would be more effective. The next big idea came in more recent years, as scientists devised temperature-sensitive liposomes. Heat them and they pop, releasing the drugs just when you need them to. From stealth to non-stealth in a matter of seconds, and right on target. Fortunately, they were able to make it work, but unfortunately, not at temperatures that didn’t essentially cook patients from the inside – sort of defeating the purpose of keeping the chemo at bay to reduce collateral damage. They failed to perform at tolerable levels of heat or time. Fifteen minutes of baking and still only 40% or so of the drug was released, and it took temperatures up to 112° Fahrenheit. It might not sound like much, but it was enough to be intensely painful and damaging as well. That’s where Celsion came in. It’s designed and developed a novel form of these temperature-sensitive chemo sacks – the first of their kind to work effectively and safely – otherwise known as a lysolipid thermally sensitive liposome (LTSL). Celsion’s liposomes are engineered to release their contents between 39-42° C, or 102.2-107.6° F (thus, another translation of LTSL has become “low-temperature sensitive liposome”). And they release the contents at an extremely fast rate, to boot. A Better Way to Use Chemo These unique properties of Celsion’s LTSL technology make it vastly superior to previous liposome technology for a number of reasons. For starters, the temperature range is much more tolerable to patients and won’t injure normal tissue. Payers should be easily convinced to cover the new therapy at profitable rates. In the modern world of health care, failure of a treatment to garner coverage from government medical programs like Medicare and the UK Health Service, and private insurance companies (which generally cooperate closely to decide how to classify and whether to cover a treatment) is usually a game-ender. Payers have a responsibility not just to patients but to their shareholders or taxpayers to stay financially solvent. This means that if a therapy does not provide a compelling cost/benefit ratio, then it won’t be covered. For instance, if you release a new painkiller that is only as effective as Tylenol and costs $1,000 per dose, you’re obviously not going to see support.center_img Second, the temperature range takes advantage of the natural effect mild hyperthermia has on tumor vasculature. Numerous studies have shown that temperatures between 39-43° C increase blood flow and vascular permeability (or leakiness) of a tumor, which is ideal for drug delivery since the cancer-killing chemicals have easy access to all areas of the tumor. These effects are not seen at temperatures below this threshold, and temperatures above it tend to result in hemorrhage, which may reduce or cease blood flow, hampering drug delivery. It’s the Goldilocks Effect: The in-between range is perfect. The market must be measurable and addressable. There must be some way to say specifically how many patients would benefit from a therapy, and to ensure that those patients have providers caring for them that would make efficient distribution of the therapy possible. For instance, a successful treatment for Parkinson’s disease might be applicable to hundreds of thousands of patients, with little competition from other treatments, whereas a treatment for Von Hippel-Lindau (VHL) might only reach hundreds. If the goal is to recover years of research investment and profit above and beyond that, then market size matters, as do current and future competitors that might limit your reach within a treatment area.last_img read more

Were beginning to approach oversold territory and

first_img We’re beginning to approach oversold territory and, as you probably already know, how soon we get to those lows will depend on how quickly the powers-that-be take the remaining slices.  A re-read of Ted’s quote above would be useful at this point. And as I type this paragraph, the London open is just under ten minutes away.  Gold, platinum and palladium prices are unchanged—and silver is up a nickel.  Gold’s net volume is very light at just under 11,500 contracts—virtually all of it of the HFT variety—and silver’s net volume is around 4,200 contracts, with decent roll-overs out of July already.  And after rallying about 20 basis points in the early going in Hong Kong trading on their Friday morning, the dollar index is back to unchanged.  Without doubt, all eyes will be on the job numbers this morning in New York—and what trading ‘action’ will accompany their release. Of course the job numbers should make no difference to the gold price at all, but a long history shows that JPMorgan et al use that as an excuse on many occasions to drive the precious metal prices into the dirt—and I’ll be amazed if that doesn’t happen this morning. Today we get the Commitment of Traders Report for positions held at the close of COMEX trading on Tuesday—and I doubt if we’ll see much, if any, improvement in the Commercial net short positions in either gold or silver, as the reporting week was pretty flat from a price perspective.  All the price action that mattered most didn’t start until the day after the cut-off—and it’s a very safe bet that it was no accident that it happened this way, as “da boyz” have used this trick for at least a decade when they want to hide their tracks for as long as possible. We also get the companion Bank Participation Report as well.  This is data that’s extracted directly from the COT Report—and shows what the world’s banks have been up to during the month that was and, as I always say at this juncture, they’re usually up to quite a bit.  I’ll have all that data in my Saturday column. And as I send the Friday edition of today’s column out the door at 5:25 a.m. EDT, I see that gold began to develop a slight negative bias starting at 2 p.m. Hong Kong time on their Friday afternoon. Ditto for silver.  Gold is down a couple of bucks, but silver is still up a nickel.  Platinum and palladium are trading flat. Gold’s net volume is now a bit over 22,000 contracts—and silver’s net volume is pretty decent as well at 6,500 contracts, but there’s been no increase in roll-over activity from over two hours ago. The dollar index was slowly heading south, but has recovered a bit in the last half hour—and is currently down only 3 basis points. As I said above, all eyes will be on the 8:30 a.m. EDT jobs report—and if you’re feeling a bit like that poor chap in the last cartoon posted above, I’ll certainly understand—as I feel that way myself at the moment. Enjoy your weekend, or what’s left of it if you live west of the International Date Line—and I’ll see you here tomorrow. Here’s the 5-minute gold tick chart courtesy of Brad Robertson.  As you can tell by the volume spikes, “da boyz” stuck it to the Managed Money traders real good once again during the COMEX trading session.  Midnight Wednesday is the vertical gray line—and you have to add two hours for EDT—and the ‘click to enlarge’ feature is a must. The silver chart was similar to gold’s, right up until 3:30 p.m. in the New York Access market.  At that point a willing seller stepped in and ensured that silver closed on its absolute low tick of the day. The high and low ticks were reported by the CME Group as $16.50 and $16.065 in the July contract. Silver finished the Thursday session at $16.075 spot, down 40 cents on the day.  Gross volume was very decent, as was net volume—46,000 contracts. Avrupa and Antofagasta intersect copper-rich VMS in Pyrite Belt, Portugal •             First Greenfields discovery of massive sulfide mineralization in 20 years in the Iberian Pyrite Belt •             10.85 meters of massive and semi-massive/stockwork sulfide mineralization grading 1.81% Cu, 2.57% Pb, 4.38% Zn, 0.13% Sn, and 75.27 ppm Ag •             Including 7.95 meters @ 2.21% Cu, 3.05% Pb, 4.82% Zn, 0.15% Sn, 89.8 ppm Ag •             Followed by 2.90 meters @ 0.71% Cu, 1.27% Pb, 3.17% Zn, 0.092% Sn, 35.4 ppm Ag •             Avrupa and Antofagasta sign an amended Joint Venture Agreement Please visit our website to learn more about the company and current exploration program. Platinum prices were a mini version of the gold price chart—and palladium was a mini version of the platinum chart.  Platinum closed on Thursday at $1,098 spot, down three bucks, finally cracking the $1,100 spot price to the downside.  Palladium also closed 3 dollars lower at $753 spot.  Here are the charts. The CME Daily Delivery Report for Day 5 of the June delivery month showed that zero gold and 9 silver contracts were posted for delivery within the COMEX-approved depositories on Monday.  Nothing to see here. The CME Preliminary Report for the Thursday trading session showed that gold open interest for June dropped another 282 contracts, leaving 1,262 still open.  June o.i. in silver was up 7 contracts to 40. There was no reported change in GLD, but another deposit was made in SLV.  This time it was 1,433,379 troy ounces.  So far this week, there has been a bit over 2.5 million ounces deposited in SLV.  Since the price action indicates that silver should be flowing out of that ETF, the deposits must have been used to cover an existing short position.  We’ll have to wait until about June 23 when the next short position report comes out of the folks over at shortsqueeze.com in order to get a hint of what might be going on. Since yesterday was Thursday, Joshua Gibbons, the Guru of the SLV Bar List, updated his website with the goings-on over at the iShares.com Internet site at the close of trading on Wednesday—and this is what he had to report. “Analysis of the 03 June 2015 bar list, and comparison to the previous week’s list:  1,138,121.2 troy were added (all to Brinks London), 893,539.6 oz were removed (all from Brinks London), and 113 bars had serial number changes.” “The bars removed were from: Solar Applied Materials (0.3M oz, Krasnoyarsk (0.2M oz), and 10 others.  The bars added were from: Krasnoyarsk (0.2M oz), Prioksky (0.1M oz), and 13 others. “As of the time that the bar list was produced, it was overallocated 384.9 oz.  All daily changes are reflected on the bar list.” Over at Switzerland’s Zürcher Kantonalbank for the week ending May 29—they reported tiny declines in both their gold and silver ETFs.  Their gold ETF shed 1,804 troy ounces—and their silver ETF dropped only 7,123 troy ounces. After four straight day of sales, it should come as no surprise that there was no report from the U.S. Mint yesterday. Over at the COMEX-approved depositories on Wednesday, there was 50,092 troy ounces of gold transferred from Canada’s Scotiabank to HSBC USA.  Other than that, there was no activity worth mentioning, but the link to what there was, is here. It was another huge in/out day in silver, as 411,788 troy ounces were received—all at JPMorgan’s vault—and 1,012,058 troy ounces were shipped out.  All of the ‘out’ movement was from Canada’s Scotiabank, including the 411,788 troy ounces that JPMorgan received.  The link to that action is here—and it’s worth a quick look. There wasn’t a lot of activity at the COMEX-approved gold kilobar depositories in Hong Kong on their Wednesday, as only 775 kilobars were reported received—and another 475 were shipped out.  All of the action was at Brink’s, Inc. as usual.  The link to that activity is here. I have a fair number of stories for you today—and I’ll happily leave the final edit up to you. Since we penetrated for the first time to the downside the key 50-day moving average in silver on Wednesday, I suppose the official price take-down cycle is now in effect. Gold, you’ll remember, had penetrated its 50-day moving average a week or so ago, so the market structure there is more advanced than it is in silver. Therefore, in silver, it’s more a question of how many contracts the commercials can induce the managed money traders to sell than it is how low prices must fall. It’s more about contracts sold than prices, although successive lower prices (salami slicing) are necessary to effect the full contract count outcome. In other words, it’s not necessary that we drop dramatically in price, just enough—and in the manner necessary to accomplish whatever complete managed money selling results this go around. Of course, please dismiss any suggestion that I (or anyone else) know for sure the direction of prices in the short term. This is about probabilities based upon the same thing that those probabilities have always been based on – past and prospective COT patterns. And even though those probabilities suggest lower silver prices ahead, any such decline should prove minor compared to the eventual much higher prices that the actual fundamentals and facts point to. While I hope my COT analysis is beneficial, please understand it is not my intent to handicap silver prices in the short term, although many others do seem so engaged. Instead, my intent is to use my analysis of the COT market structure to show just how screwed up is the price discovery process on the COMEX and, after 30 years, it is encouraging to see that at least one silver miner may feel the same. In the unfortunate circumstance that the probabilities once again prove correct and we do witness further declines in the price of silver, perhaps that might aid in convincing other silver producers to step up to the plate and write to the CFTC. Trying to come up with rational explanations for why silver and gold prices behave as they do, while leaving out the COT market structure on the COMEX, is guaranteed to reduce one to the babbling idiot level. —  Silver analyst Ted Butler: 05 June 2015 Another day—and more salami slicing in the all four precious metals, particularly gold and silver.  There was decent volume associated with both metals, so it’s an absolute certainty that the Managed Money was puking longs and piling on the short side, while JPMorgan et al gobbled up everything on the opposite side of those trades for fun, profit and price management purposes.  And it was a very profitable day for “da boyz” yesterday. Here are the 6-month charts for all four precious metals—and new lows were engineered in three of the four precious metals. The gold stocks opened down—and chopped more or less sideways for the remainder of the day, as the HUI closed down another 1.35 percent. It was more or less the same thing in the silver equities, although the trading day had more shape to it.  The big drop because someone sold a boat load of shares in Peñoles right at the close, at least that’s what Nick said yesterday when I asked him.  Because of that, Nick’s Silver Sentiment Index got hit for 2.26 percent.  Without that share dump, the loss would have been about 0.5 percent. Without doubt, all eyes will be on the job numbers this morning The gold price chopped around, mostly lower, during the Far East trading session on their Thursday—and both the rally attempt in the Far East—and the one in early London trading, met with a resolute seller the moment that the price attempted to break above unchanged.  JPMorgan et al, HFT algorithms in hand, did the dirty starting the moment that COMEX trading began—and by around 11:20 a.m. EDT, their work was done for the day, with another low for this move down.  The gold price rallied quietly after that, before chopping sideways starting around 2:40 p.m. in electronic trading. The high and low tick were recorded as $1,186.60 and $1,172.40 in the August contract. The gold price closed in New York yesterday at $1,176.40 spot, down another $8.60 from Wednesday’s close.  Net volume was very decent at 148,000 contracts. Here’s the 6-month U.S. Dollar chart as a reference. The dollar index finished the Wednesday trading session in New York at 95.37—and traded virtually ruler flat until about 1:30 p.m. Hong Kong time.  At that juncture it rallied 20 basis points, hitting 95.56 at 8:30 a.m. BST in London trading.  It fell of a cliff at 9 a.m. right on the button, hitting its 94.72 low about thirty five minutes later.  Then at noon BST it appeared that ‘gentle hands’ showed up—and the dollar rallied to a handful of basis points above unchanged minutes before trading began in the equity markets in New York.  It rallied higher from there in a rather choppy manner—and closed yesterday at 95.58—up 21 basis points from Wednesday. It’s obvious to me that the dollar would crash if given the opportunity to do so—and it’s equally as obvious that the powers-that-be are at hand to prevent that from happening.last_img read more

Healthy women with normal pregnancies can opt to h

first_imgHealthy women with normal pregnancies can opt to have labor induced without worrying that the decision will make a cesarean section more likely, according to a major study published in this week’s New England Journal of Medicine.Obstetricians currently induce labor when a delivery has failed to progress, or if a woman is far overdue for giving birth. But when women who have no medical need for induced labor have talked to their doctors, “We’ve been saying, ‘Well you know one thing you need to know is it does increase the C-section rate,’ ” says. Dr. Uma Reddy, an obstetrics researcher at the National Institute of Child Health and Human Development.That advice was based on some older medical research. But researchers had doubts about that conclusion. So Reddy helped organize a study involving more than 6,000 first-time mothers with uncomplicated pregnancies, to put the idea to the test.Half the pregnant women followed the normal course of labor; the other half had labor induced when the baby was full term, at 39 weeks. Overall, mothers and babies did fine when labor was induced with a drug.”I think the most surprising finding was a decrease in the C-section rate,” Reddy says.That rate dropped from 22 percent among the women who weren’t automatically induced to 19 percent for those whose labor was induced. Dr. William Grobman, the study’s first author and a professor of obstetrics at Northwestern University, says it’s an important goal to reduce the rate of cesarean sections in the U.S. So even a small percentage drop in the rate can have benefits overall.But an individual woman might or might not consider that 3-percentage-point drop a big deal. “I think that’s not really for me to decide,” he says. “I think that’s for patients to decide.”As expected, women who opted to have their labor induced spent more time in the labor and delivery suite.Even so, Grobman says, “I also think it’s important to recognize women who planned to be induced had fewer days in the hospital and their children had fewer days in the hospital after delivery.”The study found that women whose labor was induced were less likely to develop pre-eclampsia, an abrupt and life-threatening increase in blood pressure. Their babies were less likely to need help breathing. So all in all, it seemed medical intervention was a net plus.That was certainly the story for 33-year-old Kelli Rojek, a Chicago woman who opted into the study and whose labor was induced. She thought about the risk of having a longer labor.”The concern I was most aware of was that it can slow down labor and it can cause some headaches or nausea afterward,” she told NPR.But she also saw benefits.”It was actually rather convenient for us,” she says, “because we have a dog at home and we were able to call our families and say, ‘Hey, we’re going to go in at 11 p.m. on this day, and can you guys come up to take care of the dog and then come up to the hospital afterward?’ “Quick labor runs in her family, Rojek says. By 6:30 the next morning, her son, Harrison, came into the world.”The doctor actually told me that I should never share my story with my friends,” she says, “because they wouldn’t want to hear how fast and easy things went!”Lisa Kane Low, immediate past president of the American College of Nurse-Midwives, says the study was done well and provides useful information but that she is concerned that doctors and their patients will be nudged toward this more medical approach to childbirth.”Some of the things that go along with an induction may not be part of what they had planned for their overall birth experience,” Kane Low tells Shots. “It does require an IV, it does require that you have continuous electronic fetal monitoring to be safe, and it requires the use of different medications in order to start the labor process. And all those things need to be factored into what someone was hoping for their overall birth experience.”And the potential benefits can be hard to convey, Kane Low says.”If you say to somebody, ‘We could really reduce your risk of a cesarean by inducing your labor,’ people who are very fearful of a cesarean may say, ‘OK, I’m willing to [make that] trade-off and take the medical induction, even though that’s not what I might want because it’s going to reduce my risk.’ But, yet, the absolute reduction is very small, overall.”Plus, this study was done under optimal conditions, she notes. The hospitals all followed the latest recommendations about when to do a C-section, and the women were 23 or 24 years old, on average — which is younger than the general age of women who give birth.The March of Dimes, which has a campaign to encourage women to have full-term deliveries, issued a statement noting that because the study group was so selective, “[m]ore widespread implementation of induction at 39 weeks may yield much less favorable results, and thus should be considered with caution.”The study did not compare the overall costs of induced labor versus the traditional path — which can end in vaginal delivery, cesarean section or induced labor.Reddy agrees that there are balancing pluses and minuses behind the decision to induce labor. “I think it’s going to be up to the individual woman, because there are going to be strong opinions either way.”You can reach Richard Harris at rharris@npr.org. Copyright 2018 NPR. To see more, visit http://www.npr.org/.last_img read more

People with HIV have been failed by the government

first_imgPeople with HIV have been failed by the government’s new disability benefit, according to new research.The research by the National AIDS Trust (NAT) found that only three-fifths of people living with HIV were found eligible for the new personal independence payment (PIP) after being reassessed.NAT says its research has confirmed long-standing fears that people with HIV would not receive the support they needed under PIP, which is supposed to help cover people’s extra disability-related costs.Its report shows that only three-fifths (63 per cent) of the 1,000 people with HIV who were previously receiving disability living allowance (DLA) and had been reassessed for PIP were awarded the new benefit.This compares with 73 per cent of all DLA claimants who had been reassessed and were awarded PIP, according to the figures, published by the Department for Work and Pensions (DWP) last December.One charity that works with NAT, River House, described yesterday (Wednesday) how a 57-year-old man who was diagnosed last October with HIV and also had chronic obstructive pulmonary disease, had been awarded zero points after a PIP assessment in April.An appeal to the Department for Work and Pensions (DWP) – the so-called mandatory reconsideration stage – was refused in late June.By this time, his health had deteriorated even further and he was admitted to hospital, where he was diagnosed with untreatable lung cancer.He was due to receive DWP’s decision on a fresh PIP application this week, but died on Monday morning.Another River House service-user with HIV has described how he had to start using foodbanks after his PIP was suddenly stopped because he missed a renewal deadline by just two days after he was diagnosed with cancer.DWP refused to reconsider removing his PIP and he had to wait more than 16 weeks to be assessed again.He said: “From the moment that my PIP stopped, I lost the uplift in my ESA [employment and support allowance] that I received because I was now not receiving PIP.“While I waited to be assessed for PIP and again for ESA, I had to borrow small amounts of money from friends [and] organisations that support people living with HIV and I was a regular visitor to local food banks.”The NAT analysis also shows that people with HIV who had been claiming DLA were more likely (43 per cent) than the average DLA claimant (30 per cent) to see their level of support cut if they were awarded PIP after a reassessment.According to last December’s figures, only about 1,000 of the 7,920 people living with HIV who were claiming DLA at the start of the PIP rollout in 2013 – which itself was about 10 per cent of all those with HIV in the UK – had been reassessed.The charity says that not everyone living with HIV in the UK has benefitted equally from modern treatments – for example, long-term survivors and people diagnosed late – and some will have life-long health problems as a result of HIV. One study found that two-thirds of people living with HIV in the UK have at least one other condition, in addition to HIV, and 38 per cent have more than one additional condition.Deborah Gold, NAT’s chief executive, said: “The evidence so far is that PIP is not working for people living with HIV who need extra support.“The assessment is not fit for its stated purpose, to identify the disability-related barriers to participation and independence experienced by people living with HIV. “The tick-box eligibility criteria describe only the most basic aspects of existence, such as physical capacity to consume food and bathe, without any understanding of the social context of life with a serious long-term condition.”Among the charity’s many concerns about the assessment process are that it fails to accurately capture: the risk of isolation due to HIV-related anxiety; the need for support with nutrition; and the importance of adhering to HIV medication.Sarah Radcliffe, NAT’s director of policy and campaigns, said that the research – the first to be carried out into the impact of PIP on people with HIV – shows that the concerns raised when the abolition of working-age DLA was announced in 2010 were not baseless.She said the way the assessment was devised “means people living with HIV will not have their support needs identified – or where they are picked up, this will not necessarily translate to support”.And she said the social model “rhetoric” used by DWP when it introduced the new benefit – focussing on how social factors create barriers to participation for disabled people – “has not translated to reality for PIP”.Instead, she said, the PIP assessment “looks a lot like the work capability assessment’s notorious ‘tick box’ medical approach”.She added: “The descriptors used are proxies for a basic existence and not for barriers to participation or the extra costs associated with an active, independent life.“It is not too late to improve PIP for people living with HIV. The vast majority are yet to be reassessed.  “It is time to look again at PIP, from scratch, and make sure it lives up to its stated goals of promoting participation and independence.”A DWP spokeswoman said in a statement: “We introduced PIP to replace the outdated DLA system – it takes a much wider look at the way someone’s health condition or disability impacts them on a daily basis and is tailored to suit each individual’s needs.“Decisions are made following consideration of all the information provided by the claimant, including supporting evidence from their GP or medical specialist.“Under PIP, 28 per cent of claimants are now receiving the highest rate of support, compared to 15 per cent under DLA, and anyone who disagrees with a PIP decision has the right to appeal.”But DWP figures from last December also showed that fewer than half (about 126,000) of the 254,000 people previously receiving the higher rate mobility component of DLA secured the same level of mobility support when reassessed for PIP.And unpublished DWP figures obtained by DNS in March showed nearly half of disabled people subject to “planned reviews” of their eligibility for PIP were having their existing award either cut or removed completely.NAT has produced free resources on PIP for people living with HIV and the services who support themlast_img read more

11 Insaaaane Things You Didnt Know About the Founder of Crazy Eddie

first_img Learn how to successfully navigate family business dynamics and build businesses that excel. Eddie Antar died this weekend at age 68. Register Now » Jason Fell News and Trends Free Webinar | July 31: Secrets to Running a Successful Family Business Director of the Entrepreneur Partner Studio Eddie Antar (R) once known as Crazy Eddie Next Article September 12, 2016 Eddie Antar was an entrepreneur who realized the highs of business success as well as the lows of fraud and running from authorities. You might not recognize his name, but if you were alive in the late 1970s and 1980s, you’d be hard pressed not to know his business: he was the founder of the Crazy Eddie discount electronics store chain.From his quirky TV and radio commercials, how could you forget that his prices were totally “inasaaaaaane!”Antar died on Saturday. He was 68.Born in 1947, Antar opened his first Crazy Eddie electronics store when he was in his early 20s, in Brooklyn, N.Y. With the help of his popular commercials – which aired for nearly 15 years and starred radio personality Jerry Carroll – the business grew into a small empire of stores up and down the East Coast. VCRs, video games and camcorders (remember those?) were hot sellers at the time.But Antar’s “success” wouldn’t last forever. Here’s a quick look at 11 moments during his rise and fascinatingly bizarre fall:Antar opened his first Crazy Eddie electronics store in 1969 on Kings Highway in Brooklyn.The term “crazy” came from Antar’s wild sales style. Apparently, he’d accept customers’ shoes as deposits on items like TVs or stereos.His first commercial aired in 1975. Each one ended with the phrase, “’Crazy Eddie, his prices are insaaaaaane!” He continued to open new locations in the New York metro area.Riding the brand’s popularity (those ads were memorable), Antar took the company public in 1984.At its height, the company had more than 40 locations from Boston to Philadelphia, and was generating as much as $350 million in revenue a year.By 1987, stockholders discovered that $45 million in merchandise was missing. His business and accounting practices were called into question and the stockholders staged a takeover of the company. After all, how could he have such insanely low prices?Federal prosecutors eventually charged Antar and his family of skimming cash and manipulating the company’s stock.In 1989, Crazy Eddie filed for bankruptcy and its final store closed.The following year, Antar fled the country and was later found living in Israel. He was extradited and served seven years in U.S. prison.Antar’s cousin, Sam, who was the company’s CFO, pleaded guilty to fraud and later served as a consultant to governmental agencies that were investigating accounting fraud.In 2001, a newly freed Antar attempted to bring Crazy Eddie’s back, selling electronics online. Despite the cheesy ads, there wasn’t enough steam in the brand for a second go and the company failed. Add to Queue –shares 11 Insaaaane Things You Didn’t Know About the Founder of Crazy Eddie 3 min read Entrepreneur Staff Image credit: Sven Nackstrand/AFP | Getty Imageslast_img read more

The Evolution of Audio Advertising and Whats Next in 2020

first_imgWhile audio advertising has been relatively consistent for the better part of 50 years, it’s now going through a massive transformation. It’s no longer as simple as putting out a big (and often impersonal) ad campaign in an effort to reach the people you’re trying to reach. Today, it’s all about reaching the right people via the right platform at precisely the right moment while giving them a much more targeted and personalized experience.Over the past 15 years, we’ve watched the industry progress from “radio” to “audio” and the strengths of the medium develop from reliable to innovative. In the spirit of reflection, it’s interesting to examine just how much audio advertising has evolved.These are some of the biggest changes we’ve seen:Opportunities GaloreIt’s hard to imagine, but before 2000, the mainstays of today’s audio landscape barely existed– satellite radio, streaming and podcasts were just starting to emerge. Of course, these channels have exploded in popularity and continue to evolve rapidly, opening up a dearth of opportunities for brands to connect with new audiences. Unlike TV and digital ads, audio ads don’t have to compete with other ads for eyeballs or work within the space confines of a screen.Today’s listeners are much more tuned in and engaged with what they’re listening to, providing greater opportunities for advertisers to reach them.Podcast listeners, for example, have been shown to be so invested in their favorite shows that they actively listen to ads contained within the episode. And, if a podcast host endorses a particular product, even better as listeners tend to be more open to the product. Even with the availability of ad-free streaming services, millions of listeners opt to listen to the ad-supported versions of Spotify and Pandora, again giving brands the chance to share their products and services with a more engaged audience.Content ExplosionNaturally, the rise of these opportunities goes hand in hand with the explosion of audio content. While years ago talk radio dominated the audiowaves, podcasts are taking center stage.  There are over 600,000+ active podcasts shows catering to just about every topic or interest imaginable.With podcasts, listeners hear exactly what they want to hear, exactly when they want to hear it, giving advertisers the ability to reach exactly who they want to reach when they want to reach them.One of the biggest advantages for an advertiser of endorsed audio is the “host trust factor.”When your favorite host or influencer tells you how much they love a product or service, loyal listeners activate and buy that product or service.More FragmentationOf course, with more opportunities and content comes more fragmentation. From 1922 when the first radio ad ran to even 10 years ago, AM/FM radio was a straight shot for an advertiser looking to connect with Americans en masse.But with so many opportunities to reach target audiences today, how do advertisers decide where to invest their dollars? Yes, audiences are much more engaged, but what about search and discovery?  With 120,000 podcasts launched in the last year alone how do advertisers find the shows or identify the hosts or influencers that will best align with their products?One big way advertisers are combating these challenges is through AI.  AI technology (like our aiWARE platform) can surface tons of data to find what’s most meaningful to brands, discover new content, find the right podcast influencer and help guide brands to making smart, cost-effective decisions around their ad spend.What’s On The Horizon?As we usher in 2019, we look forward to watching the audio advertising landscape continue to evolve. We expect that audio content, especially podcasts and voice-enabled devices, will become more unique and personalized.We also expect podcasts will continue to become mainstream and even get closer to finding the listener (instead of the listener looking for the podcast).While these opportunities and content expand, we believe that AI will continue to guide audio advertisers on their quest to delivering a more meaningful and personalized customer experience.If we’ve learned anything in the last few years it’s that the audio space is full of surprises. As the industry continues to innovate, advertisers will need to keep pace and challenge themselves to take full advantage of the opportunities that await. Thirty years in the media business and involved in over $1 billion of ad campaigns.One thing is certain, AUDIO IS BACK! The Evolution of Audio Advertising and What’s Next in 2020 Zeus PeleusesJune 3, 2019, 8:23 pmJune 3, 2019 AIAudio AdvertisingAudio Contentcontent marketingpodcastsprogrammatic advertisingRadio AdvertisingTV adsVeritone One Previous ArticlePernix Launches Attribution Application Solution to Brings Full Transparency to Performance Marketing ProgramsNext ArticleUpland Software Acquires Kapost, Raises Guidancelast_img read more